Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Other Non-Current Assets (2024 - 2025)

Madrigal Pharmaceuticals (MDGL) has disclosed Other Non-Current Assets for 8 consecutive years, with $5.0 million as the latest value for Q3 2025.

  • Quarterly Other Non-Current Assets changed 0.0% to $5.0 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $5.0 million through Sep 2025, changed 0.0% year-over-year, with the annual reading at $5.0 million for FY2024, N/A changed from the prior year.
  • Other Non-Current Assets for Q3 2025 was $5.0 million at Madrigal Pharmaceuticals, roughly flat from $5.0 million in the prior quarter.
  • The five-year high for Other Non-Current Assets was $5.0 million in Q2 2024, with the low at $5.0 million in Q2 2024.